• HPR69 Evaluation of Availability, Prices and Affordability of Breast Cancer Medicines in Kwara-Central Senatorial District, Nigeria

    Dec 1, 2022, 00:00

  • EE408 Economic Evaluation of Endovascular Therapy for Acute Stroke With a Large Ischemic Region in China

    Dec 1, 2022, 00:00

  • HSD115 Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec

    Dec 1, 2022, 00:00

  • HPR134 Health Policy Analysis of Written Question Motions Submitted to the Presidency and Ministries by the Deputies Between 2018–2022 in Turkiye

    Dec 1, 2022, 00:00

  • EPH187 Effects of Non-Pharmaceutical Interventions (NPIS) Aimed at Limiting the Spread of SARS-COV-2

    Dec 1, 2022, 00:00

  • EE102 Economic and Organisational Impact of an Innovative Treatment With Extended Durability for Retinal Diseases Reducing the Annual Frequency of Intravitreal Injections in France

    Dec 1, 2022, 00:00

  • RWD112 Can ML-Extracted Variables Reproduce Real World Comparative Effectiveness Results From Expert-Abstracted Data? A Case Study in Metastatic Non-Small Cell Lung Cancer Treatment

    Dec 1, 2022, 00:00

  • EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland

    Dec 1, 2022, 00:00

  • CO45 Real-World Clinical Outcomes of Secukinumab in Thai Patients With Psoriasis: Subgroup Analyses By Adherence Rate and Completeness of Loading Dose

    Dec 1, 2022, 00:00

  • PCR31 Patient and Caregiver Preferences for the Treatment of Duchenne Muscular Dystrophy: A Quantitative Patient Preference Study

    Dec 1, 2022, 00:00

  • HPR207 Are the Incremental Added Benefit and Price Claimed in Agreement With the Clinical Evaluation and the Price Setting? A Retrospective Analysis in France (2016-2021)

    Dec 1, 2022, 00:00

  • HTA34 Quo Vadis Benefit Assessment for Orphan Drugs in Germany: The End of the Exception?

    Dec 1, 2022, 00:00

  • EPH126 Sex- and Age-Adjusted Incidence and Prevalence Population-Based Estimation for Acute Myeloid Leukemia in Korea From 2011 to 2019

    Dec 1, 2022, 00:00

  • CO81 A Bayesian Approach to Increase Evidence of Effectiveness in Health Economic Evaluations of Treatments for Rare Diseases

    Dec 1, 2022, 00:00

  • EE311 Polyethylene Glycol Hydrogel Versus Fibrin Glue Sealant for Posterior Fossa Surgery: A Budget-Impact Analysis in Five European Countries

    Dec 1, 2022, 00:00

  • CO48 Systematic Literature Review and Meta-Analysis of Endoscopic Improvement for Treatment of Moderate-Severe Ulcerative Colitis

    Dec 1, 2022, 00:00

  • RWD8 Patient Preferences in Chronic Immune-Mediated Inflammatory Diseases Potentially Treated With Biological Drugs: Real-World Data Analysis

    Dec 1, 2022, 00:00

  • PCR237 Effect of Eptinezumab on Utility Scores in Patients With Migraine: Results From the Deliver Study

    Dec 1, 2022, 00:00

  • PCR154 Modelling Time-to-Death Utilities as a Continuous Function, Using a Rich Dataset of Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

    Dec 1, 2022, 00:00

  • PCR83 Investigation of Functional Outcomes at Hospital Discharge in Hip Replacement Patients in Different Health Care Sectors

    Dec 1, 2022, 00:00

  • MSR31 Evidence Synthesis for Decision-Making: Is Meta-Analysis Always Required?

    Dec 1, 2022, 00:00

  • MT15 Obvio-19 App Ease of Use of Cancer Patients for Reporting COVID-19 Symptomology (ONCOVID Study)

    Dec 1, 2022, 00:00

  • EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

    Dec 1, 2022, 00:00

  • HTA102 Machine-Learning Technology Assisted Curated Reference Libraries as an Approach for Rapid Global Value Dossier Updates to Support Living Health Technology Assessment: A Case Study in Triple Refractory Multiple Myeloma (TRMM)

    Dec 1, 2022, 00:00

  • EE567 Environmental Impact and Sustainability of Surgical Sets: The 4S Approach

    Dec 1, 2022, 00:00

  • EPH70 Transcription Errors in Ophthalmology: Current Burden and the Opportunity for Digital Technologies

    Dec 1, 2022, 00:00

  • PCR5 Healthcare Resource Use, Productivity and Quality of Life in Patients With Migraine: Results from Overcome (EU) Study

    Dec 1, 2022, 00:00

  • MSR54 A Comparison of MAIC and STC Methods to Support the Decision at Feasibility Assessment Stage

    Dec 1, 2022, 00:00

  • HPR183 Could Netflix Based Subscription Models Tackle the Shrinking Antibiotic Pipeline?

    Dec 1, 2022, 00:00

  • HPR149 Global Pricing, Reimbursement and Market Access Trends for Regenerative Medicines, ATMPs, Cell, Gene Therapies

    Dec 1, 2022, 00:00

  • EE338 The Potential Benefit of Respiratory Syncytial Virus (RSV) Vaccination in Older Adults: A Comparison of the United States (US) and United Kingdom (UK)

    Dec 1, 2022, 00:00

  • P19 How Is Real-World Evidence Really Being Used in Health Technology Assessments – A Canadian Case Study

    Dec 1, 2022, 00:00

  • HPR26 Anti-PD(L)1: Does the Cost of Treatment Have an Impact on the Therapeutic Decision-Making?

    Dec 1, 2022, 00:00

  • RWD126 Introducing the German MSDS-AOK PLUS Database: Linkage of Administrative Claims Data and a Patient Registry for Advanced RWE Capabilities in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • PCR236 Estimating Health Utilities for Health States of Patients With Stroke Using the SF-6D

    Dec 1, 2022, 00:00

  • CO146 Potential Predictors Affecting Access to Breast Cancer Screening Among Women in the United States Using the Health Behavioral Model: A MEPS Panel Analysis

    Dec 1, 2022, 00:00

  • HTA187 Best Practices for the Development of Budget Impact Models at Regional Level

    Dec 1, 2022, 00:00

  • CO7 Evaluating Health Outcomes and Costs Related to In-Hospital Procedures for the Management of Mitral Valve Disease in Spain

    Dec 1, 2022, 00:00

  • EE291 Economic Evaluation of Metastatic Breast Cancer Following Trastuzumab-Based Treatment of HER2+ Early Breast Cancer in Hong Kong

    Dec 1, 2022, 00:00

  • HPR159 Neovascular Age-Related Macular Degeneration (NAMD) in Italy: A Social Cost Analysis

    Dec 1, 2022, 00:00

  • MSR92 Challenges to Implementing Real-World Evidence (RWE)

    Dec 1, 2022, 00:00

  • EPH61 Obesity and Glycemic Control Among People With Type 2 Diabetes in Europe: A Retrospective Cohort Analysis

    Dec 1, 2022, 00:00

  • HPR208 Analysis of Substitution Procurement Agreements and Financial Impact in a University Hospital Structure

    Dec 1, 2022, 00:00

  • EE121 Cost-Effectiveness of Family Based Treatment for Pediatric Obesity: A Literature Review

    Dec 1, 2022, 00:00

  • EPH103 Vitiligo in Italy Through Administrative Healthcare Data

    Dec 1, 2022, 00:00

  • HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe

    Dec 1, 2022, 00:00

  • PCR240 A Cross-Sectional Study of Disease Severity and Health Related Quality of Life in Epidermolysis Bullosa

    Dec 1, 2022, 00:00

  • EE385 Cost Effectiveness of Gender-Neutral Vaccination With Gardasil 9 Against HPV in Greece

    Dec 1, 2022, 00:00

  • EE640 Quantifying Out-of-Pocket Expenses in Patients With Prurigo Nodularis

    Dec 1, 2022, 00:00

  • PCR17 Capturing the Impact of Grief and Bereavement on Caregivers in NICE HST Appraisals

    Dec 1, 2022, 00:00

  • PCR95 Functional Quality of Life Among People Living With Obesity: A Longitudinal Cohort of Patient Reported Outcomes

    Dec 1, 2022, 00:00

  • HPR1 Development of an Economic Evaluation Guideline in Lebanon

    Dec 1, 2022, 00:00

  • SA76 Burden of Illness in Patients with Alzheimer’s Disease: A Systematic Review of Incidence, Prevalence, Comorbidities, Disability and Mortality

    Dec 1, 2022, 00:00

  • HTA5 Methodological Frameworks for the HTA of Digital Health Technologies: A National and International Survey

    Dec 1, 2022, 00:00

  • HTA201 Access Challenges of Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • EE79 Cost-Effectiveness of Earlier Whole-Genome Sequencing in Rare Genetic Childhood Epilepsy

    Dec 1, 2022, 00:00

  • HTA205 Time to Reimbursement Decisions for Personalized Medicines in the UK and France

    Dec 1, 2022, 00:00

  • P35 Real-World Evidence of Incidence, Initial Treatment, and Survival of Female Breast Cancer in Germany

    Dec 1, 2022, 00:00

  • EE661 Impact on Health-Economic Evaluations of the Extrapolation Method Regarding the Efficacy of Immunotherapies: Case Study in Renal Cell Carcinoma

    Dec 1, 2022, 00:00

  • HSD2 Reusable Soft Mist Inhalers Have an Improved Carbon Footprint Compared With Dry Powder Inhalers and Pressurised Metered-Dose Inhalers

    Dec 1, 2022, 00:00

  • CO71 EU Joint Clinical Assessment Initiative: Process and Access Strategy Implications

    Dec 1, 2022, 00:00

  • HPR7 Out-of-Pocket Health Expenditures of Households With Rare Diseases in Turkiye

    Dec 1, 2022, 00:00

  • EE251 A Budget Impact Analysis of the Introduction of Generics Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Greece

    Dec 1, 2022, 00:00

  • EPH52 Odds Ratio of Each Disease Before Incidence of Alzheimer's Disease - A Case Control Study Using Japanese Health Insurance Claims Data

    Dec 1, 2022, 00:00

  • EE571 Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection With or Without Resistan A UK Perspective

    Dec 1, 2022, 00:00

  • PCR125 Censoring in the Time Trade-Off Valuation of Worse-Than-Dead EQ-5D-5L Health States: Can a Willingness-to-Accept Question be the Solution?

    Dec 1, 2022, 00:00

  • HPR43 Differences in Inequalities of Uterine Cancer Treatment Before and After COVID-19 in England

    Dec 1, 2022, 00:00

  • HTA232 Indirect Treatment Comparison Methods in NICE Immuno-Oncology Technology Appraisals: Implementation and Critique

    Dec 1, 2022, 00:00

  • HPR209 The Unmet Medical Needs Concept – A Structured Analysis of Its Application in Authorisation and Belgian Reimbursement Practices

    Dec 1, 2022, 00:00

  • HTA71 Will the New EU HTA Regulations Increase the Methodological Requirements to Conducting Systematic Literature Reviews of Clinical Evidence?

    Dec 1, 2022, 00:00

  • EPH45 Socio-Demographic Determinants of Childhood Vaccination in Indonesia: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis

    Dec 1, 2022, 00:00

  • HTA126 Procedural Issues in Health Technology Assessment (HTA) for Re-Pricing in Japan

    Dec 1, 2022, 00:00

  • EE48 Can We Afford to Overlook the Cost of Avoidable Complications in Type 2 Diabetes: A Health Economic Analysis to Evaluate What Is the ‘Cost of Not’ Acting in Turkey?

    Dec 1, 2022, 00:00

  • HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?

    Dec 1, 2022, 00:00

  • MT24 Oxidized Zirconium Can Positively Impact Outcomes in Revision Arthroplasty: A 90-Day Episode of Care Analysis in a Large US Metropolitan Statistical Area (MSA) Following Revision Knee (RKA) and Hip Arthroplasty (RHA)

    Dec 1, 2022, 00:00

  • PCR84 Myasthenia Gravis Patients Have Lower Eq-5D-5L and HUI3 Utility Values Than a Matched Sample of the General Population: Analysis of Digitally Collected Observational Data from 8 Countries

    Dec 1, 2022, 00:00

  • EE122 Estimating Hospital Care Costs Associated With Excess Physical Comorbidities in Patients With Mental Health Disorders in Europe

    Dec 1, 2022, 00:00

  • EPH136 Landscape of Dyslipidemia in China

    Dec 1, 2022, 00:00

  • CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

    Dec 1, 2022, 00:00

  • MSR142 Combination State Sequence and Process Mining Approach to Develop a Patient-Level Model of Heterogenous Clinical Pathways in Osteoporosis

    Dec 1, 2022, 00:00

  • SA19 A Systematic Literature Review of the Economic Burden of Surfactant Use in the Treatment of Neonates with Respiratory Distress Syndrome

    Dec 1, 2022, 00:00

  • PCR9 Development and Evaluation of Gaucher Disease-Specific Patient Reported Outcome Measurement in Japan

    Dec 1, 2022, 00:00

  • PCR264 Quality of Life and Disability Among Patients With Chronic Lower Back Pain

    Dec 1, 2022, 00:00

  • PCR23 Humanistic Burden and Mental Conditions Among Cancer Patients Before and During the COVID-19 Pandemic in Japan and China

    Dec 1, 2022, 00:00

  • PCR230 Understanding the Indirect Burden of Patients and Caregivers Impacted by Refractory/Relapsing Multiple Myeloma

    Dec 1, 2022, 00:00

  • EE576 Potential Budget Impact of Negative Pressure Wound Therapy (NPWT) Versus Conventional Wound Treatment in Diabetic Foot Ulcers (DFU), Surgical and Trauma for Selected Countries in Latin America

    Dec 1, 2022, 00:00

  • HTA246 The SMC Ultra-Orphan Framework: 3-Year Report Card

    Dec 1, 2022, 00:00

  • SA15 Propensity Score Matching: Role of Clinical Expertise in a Data-Driven Approach to Model Selection

    Dec 1, 2022, 00:00

  • PCR103 Patients and Neurologists’ Preferences for Remote Patient Monitoring and Artificial Intelligence to Improve Parkinson's Disease Management

    Dec 1, 2022, 00:00

  • MSR100 Applicability of Artificial Intelligence in Targeted Literature Review

    Dec 1, 2022, 00:00

  • EE518 An Early Cost-Effectiveness Analysis of Minimally Invasive Paddle-Type Spinal Cord Stimulation for the Treatment of Chronic Neuropathic Pain

    Dec 1, 2022, 00:00

  • HTA61 Challenges in Selecting Relevant Comparator Therapies in Indications With Low Evidence Using the Example of German Benefit Assessments With the Appropriate Comparator Therapy “Treatment of Physicians Choice"

    Dec 1, 2022, 00:00

  • PCR25 Content Validity Assessment of a Newly-Developed Patient-Reported Outcome Measure for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

    Dec 1, 2022, 00:00

  • HPR106 The Challenges of Outcomes-Based Reimbursement for Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • HTA244 Inclusion of Carer Health-Related Quality of Life (HRQOL) in National Institute for Health and Care Excellence (NICE) Appraisals Published Since 2019

    Dec 1, 2022, 00:00

  • MSR117 Are Classifiers the Future of Artificial Intelligence in Systematic Literature Reviews?

    Dec 1, 2022, 00:00

  • RWD5 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Pompe Disease in England

    Dec 1, 2022, 00:00

  • MSR29 Benchmarking Current Practices in Data Visualisation in HEOR, Identifying Gaps and Suggesting Improvements

    Dec 1, 2022, 00:00

  • MSR67 Automation of Abstract Screening: A Case Study of Multiple Systematic Literature Reviews

    Dec 1, 2022, 00:00

  • EE88 Impact of Rational Use of Palivizumab in the Treatment of RSV in a Private Health Insurance Company in Brazil

    Dec 1, 2022, 00:00

  • PCR204 Qualitative Debriefing of the Cystic Fibrosis-Impact Questionnaire (CF-IQ) Among Adolescents With Cystic Fibrosis (CF)

    Dec 1, 2022, 00:00

  • EE383 The Economic Burden of COVID-19 Prevention and Cases Management in Egypt from Governmental Perspective

    Dec 1, 2022, 00:00

  • EE319 Building a Cost-Effectiveness Model for Hypertrophic Cardiomyopathy: A Literature Review

    Dec 1, 2022, 00:00

  • SA51 Different Ways to Present a DCE to Respondents: A Scoping Review

    Dec 1, 2022, 00:00

  • HPR97 National Reimbursement Drug List Negotiation in China: Analysis of the Key Trends and Factors Influencing the Value Appraisal and Price Determination

    Dec 1, 2022, 00:00

  • CO29 The Very Long-Term Durability of TEVAR for Traumatic Aortic Transection Determined by Real-World Evidence

    Dec 1, 2022, 00:00

  • SA29 Adopting Clinical Trial Best practices of Hybrid Decentralized and Risk Based Quality Management (RBQM), to Help Optimize Prospective Observational (Real-World Evidence) Studies in Compliance, Cost and Time Criteria

    Dec 1, 2022, 00:00

  • EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

    Dec 1, 2022, 00:00

  • EE393 Cost Effectiveness Analysis of DTG/3TC Versus EVG/c/TAF/FTC and BIC/TAF/FTC for HIV-1 Infection Management in Treatment-Naïve Patients in China

    Dec 1, 2022, 00:00

  • P20 Health Technology Assessment Based on Real-World Data: Estimating Lifetime Survival and Costs With Empirical Examples from Taiwan

    Dec 1, 2022, 00:00

  • EE556 Anti-VEGF Cost Calculator in Wet Age-Related Macular Degeneration and Diabetic Macular Edema in Portugal

    Dec 1, 2022, 00:00

  • MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies

    Dec 1, 2022, 00:00

  • HTA258 Health Technology Assessments of Single-Arm Clinical Trials in Germany and France

    Dec 1, 2022, 00:00

  • EE619 The Economic Impact of Empagliflozin in Adult Patients With Chronic Heart Failure in Spain

    Dec 1, 2022, 00:00

  • PCR51 Reassessing the Acceptability of Risk of Death Associated With Gene Therapy for Duchenne Muscular Dystrophy: A Qualitative Study to Inform Updating a Quantitative Instrument

    Dec 1, 2022, 00:00

  • P12 Addressing the Distributional Consequences of Spillovers in Health Economic Evaluation: A Prioritarian Approach

    Dec 1, 2022, 00:00

  • HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment

    Dec 1, 2022, 00:00

  • EE510 A Global Analysis of the Value of Precision Medicine in Oncology – The Case of Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE261 Cost and Resource Studies in Endometriosis: An Evidence Map

    Dec 1, 2022, 00:00

  • PCR157 The Impact of Single Pill Combination Versus Free Dose Equivalent on Outcomes in Patients With Hypertension and/or Dyslipidaemia: A Systematic Review

    Dec 1, 2022, 00:00

  • CO60 Mortality Impact Following the EU Approval of Numerous Novel Non-Small Cell Lung Cancer (NSCLC) Therapies Between 2010-2020

    Dec 1, 2022, 00:00

  • RWD54 Healthcare Resource Use and Associated Costs of Congenital Thrombotic Thrombocytopenic Purpura in France

    Dec 1, 2022, 00:00

  • HTA207 Managed Entry Agreements in the Context of Health Technology Assessment Recommendations in Ukraine: Analysis on the Stage of Development

    Dec 1, 2022, 00:00

  • PCR94 Difference in Health-Related Quality of Life Among People With and Without Disabilities

    Dec 1, 2022, 00:00

  • HPR34 Emerging Role of Patient Reported Outcomes in Drug Approval in Europe

    Dec 1, 2022, 00:00

  • Analytic Methods for the Effectiveness of Immunotherapies in Oncology

    Dec 1, 2022, 00:00

  • EE615 Economic Burden and Quality of Life in Prurigo Nodularis: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE391 Impact of the COVID-19 Pandemic on the Healthcare Resource Use of People With Newly Diagnosed Mood/Affective Disorder

    Dec 1, 2022, 00:00

  • HPR205 Future-Proofing European Regulatory and Market Access Practices Based on Learnings From the COVID-19 Pandemic – Stakeholder Perspectives

    Dec 1, 2022, 00:00

  • HTA193 Criteria for Value Assessment of Medication Adherence-Enhancing Interventions: Preliminary Results of a Systematic Review

    Dec 1, 2022, 00:00

  • EPH105 Changes in the Prevalence of Gestational Diabetes Mellitus and Associated Syndromes of Infants — The Case of Hungary

    Dec 1, 2022, 00:00

  • P6 EMA/EUnetHTA Qualification of the IMI PREFER Patient Preference Framework and Points to Consider for Method Selection: Key Experiences, Outcomes, Value and Implications

    Dec 1, 2022, 00:00

  • RWD78 First Real-World Evidence Study of Patients With Hemophilia in Algeria

    Dec 1, 2022, 00:00

  • PCR132 Is Walking as Important as Communicating After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2022, 00:00

  • HSD102 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Huntington Disease-Related Chorea

    Dec 1, 2022, 00:00

  • SA43 Rapid Evidence Publication in the COVID-19 Era: Impact on Study Quality and Study Identification

    Dec 1, 2022, 00:00

  • HTA96 Health Economic Modelling for HTA Assessment: A Comparison of Economic Protocols Submitted to Three HTA Bodies (HAS, NICE, CADTH)

    Dec 1, 2022, 00:00

  • EE402 Social and Economic Burden of Breast Cancer in Russia

    Dec 1, 2022, 00:00

  • RWD69 Healthcare Resource Use by European Patients Enrolled in RA-BE-REAL: 12 Month Data From a Multinational, Prospective, Observational Study of Patients With Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EE419 Economic Evaluation of Extracorporeal Membrane Oxygenation (ECMO) vs Invasive Ventilation for COVID-19 Patients with Severe Acute Respiratory Distress Syndrome (ARDS)

    Dec 1, 2022, 00:00

  • HPR28 Last Resort for Reimbursement of New Drugs in Germany: When the Arbitration Office Must Decide

    Dec 1, 2022, 00:00

  • EE420 Valuation of Lost Productivity for Individuals Diagnosed With Osteogenesis Imperfecta: Follow-up Findings From the Rudy Cohort Study in the UK

    Dec 1, 2022, 00:00

  • EE625 Economic and Clinical Burden of Worsening Heart Failure Patients With Reduced Ejection Fraction: French National Healthcare Database Analysis (SNDS)

    Dec 1, 2022, 00:00

  • P66 Understanding of Post-COVID Conditions (PCC) and Related Burden of Illness

    Dec 1, 2022, 00:00

  • EE71 Cost-Effectiveness of Screening for Hydroxychloroquine Retinopathy

    Dec 1, 2022, 00:00

  • MSR7 Multiplicative With Linear Transformation (MLT): An Improvement on the Multiplicative Method for Age and Sex Adjustment of Utilities?

    Dec 1, 2022, 00:00

  • CO111 Evaluating Mediator Factors Affecting Breast Cancer Screening in American Women: An Application of the Andersen's Behavioral Model to 2011 to 2015 MEPS Panel Data

    Dec 1, 2022, 00:00

  • EE489 The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

    Dec 1, 2022, 00:00

  • EE409 Cost Effectiveness of Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

    Dec 1, 2022, 00:00

  • EE317 An Unresolved Paradox: The Additional Challenge of Demonstrating Cost-Effectiveness for Innovative Treatments Addressing Diseases With High Unmet Need

    Dec 1, 2022, 00:00

  • PCR62 The Australian Paediatric Multi-Instrument Comparison (P-MIC) Study: Data Quality, Feasibility, Acceptability, and Construct Validity of the EQ-5D-Y-3L, EQ-5D-Y5L, CHU9D, PedsQL, HUI, PROMIS-25 and AQoL-6D

    Dec 1, 2022, 00:00

  • EE596 Comparative Evaluation of the Health Utilities Index Mark 3 and the Short Form-6D: Evidence From an Individual Participant Data Meta-Analysis of Very Preterm and Very Low Birthweight Adults

    Dec 1, 2022, 00:00

  • EPH44 Prevalence and Risk Profile of Emerging Multidrug Resistance in Klebsiella Pneumoniae/ Enterobacteriaceae: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR188 Characterizing the Relevance of IRP for Medical Devices: A Cross-Country Comparison

    Dec 1, 2022, 00:00

  • PCR202 The Nature of Quality Appraisal in Systematic Literature Reviews of Health State Utility Values (HSUVS): A Rapid Evidence Review

    Dec 1, 2022, 00:00

  • MSR42 Adoption of Artificial Intelligence in Systematic Reviews

    Dec 1, 2022, 00:00

  • CO95 The Relationship Between Asthma Control Questionnaire Scores and Exacerbation Risk, Resource Utilization, and Utility Values: An Analysis From the Captain Trial

    Dec 1, 2022, 00:00

  • HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19

    Dec 1, 2022, 00:00

  • EE520 Cost of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) in Spain: A Delphi Approach

    Dec 1, 2022, 00:00

  • EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • HPR172 How Thalassemia Is Prevented in China: A Policy Review and International Comparison

    Dec 1, 2022, 00:00

  • RWD97 Cost of COPD Hospitalizations in the Brazilian Public Health

    Dec 1, 2022, 00:00

  • EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population

    Dec 1, 2022, 00:00

  • HSD10 Medical Cannabis Legalization and Opioid- and Pain- Related Outcomes Among U.S. Patients Newly Diagnosed With Cancer and Receiving Anti-Cancer Treatment

    Dec 1, 2022, 00:00

  • HSD108 Physician Perceptions on the Treatment and Health-Related Quality of Life Burden of Endogenous Cushing's Syndrome

    Dec 1, 2022, 00:00

  • EE577 Cost-Consequence Analysis of EPTFE Vascular Grafts With Heparin End Point Covalent Bond Compared to Standard EPTFE Vascular Grafts in Below-Knee Surgical Bypass for Critical Limb Ischaemia Pad Patients in Portugal

    Dec 1, 2022, 00:00

  • MT21 Living With Orthopaedic Implants: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • HTA158 A Comparison of HTA Economic Results in Ireland: The Applicant and Assessor Perspectives

    Dec 1, 2022, 00:00

  • RWD37 Healthcare Resource Use and Associated Costs of Dengue Fever Requiring Hospitalization: A French National Real-World Study

    Dec 1, 2022, 00:00

  • PCR29 A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

    Dec 1, 2022, 00:00

  • HTA37 The NICE Disease Severity Modifier: A Retrospective Analysis on Its Potential Impact on Previous Reimbursement Decisions in England

    Dec 1, 2022, 00:00

  • PCR197 Psychometric Evaluation of a New Electronic Pediatric Asthma Symptom Diary

    Dec 1, 2022, 00:00

  • MT32 Rise of the Machines – Analysis of Robotic-Assisted Surgery From 2005 to 2020 Based on German Hospital Data

    Dec 1, 2022, 00:00

  • CO119 Systematic Review and Meta-Analysis of Mucosal Healing Outcomes With Biologics in Treatment of Ulcerative Colitis and Crohn's Disease

    Dec 1, 2022, 00:00

  • EE666 Cost-Analysis of the Introduction of a Second Generation Biomarker Breast Cancer Prognostic Test for the Management of Early Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • HPR96 Trends in European Pharmaceutical Tender Requirements and Opportunities for Differentiation for Biosimilars

    Dec 1, 2022, 00:00

  • HTA53 Will NICE’S New Severity Weighting Criteria Be Capable of Identifying Severe Conditions?

    Dec 1, 2022, 00:00

  • RWD167 The Impact of Administration Modality on Quality of Life for Respiratory Diseases in Japan Based on Patient-Reported Outcomes

    Dec 1, 2022, 00:00

  • EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective

    Dec 1, 2022, 00:00

  • HPR6 Analysis of Patient Access to Personalized Oncology Medicines in Turkiye

    Dec 1, 2022, 00:00

  • P47 Understanding Evidence Requirements for Diagnostic Devices for Reimbursement and Market Access: Insights and Lessons From Review of NICE Diagnostics Assessment Reports (2011-2022)

    Dec 1, 2022, 00:00

  • CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)

    Dec 1, 2022, 00:00

  • EE249 Incorporating Litigation Costs in Economic Evaluation

    Dec 1, 2022, 00:00

  • HTA68 Digital Health – Where Do We Stand From a Market Access Perspective in the EU-4 and the UK?

    Dec 1, 2022, 00:00

  • EE220 Healthcare Costs of Osteoporotic Fractures in Nigeria

    Dec 1, 2022, 00:00

  • MSR79 Synthesis of Survival Outcomes in Economic Evaluation: Does the Network Meta-Analysis Model Matter?

    Dec 1, 2022, 00:00

  • P64 Health-Related Quality of Life in HER2-Positive Early Breast Cancer Woman Using Trastuzumab: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR267 Evaluating Patient-Reported Experience Along the Inflammatory Bowel Disease Patient Journey in Portugal

    Dec 1, 2022, 00:00

  • EPH180 Acute Coronary Heart Syndrom (ACS): Hospitalizations in Germany Before and During COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • PCR265 Preferences and Needs of Heart Failure Patients Regarding Their Treatment and Care

    Dec 1, 2022, 00:00

  • PCR145 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy (SMA) in Italy

    Dec 1, 2022, 00:00

  • HPR11 Could DiGA be a Role-Model for a New Digital Health Process in the UK?

    Dec 1, 2022, 00:00

  • HPR86 Sustainability of Healthcare Systems in the Wake of COVID-19: The UK VPAS Case Study

    Dec 1, 2022, 00:00

  • Frameworks and Methods for the Design of Stated Preference

    Dec 1, 2022, 00:00

  • SA53 Misdiagnosis and Disease-Exacerbating Medication Use in Patients With Neuromyelitis Optica Spectrum Disorder in the United States: A Retrospective Claims Analysis

    Dec 1, 2022, 00:00

  • MT7 Artificial Intelligence Applied to Motor Activities: A Rapid Review of the Literature

    Dec 1, 2022, 00:00

  • EE455 Assessing the Consequences of Suboptimal Infant Vaccination Rates on Pertussis Costs in Brazil: A Prospective Modeling Analysis

    Dec 1, 2022, 00:00

  • P18 Cancer Drugs Fund Entry and Exit: A Comparison of Key Issues for Decision-Making in NICE Technology Appraisals

    Dec 1, 2022, 00:00

  • HTA269 What Are the Emerging State-of-the-Art HTA Methods That Are Relevant to Harmonization of HTA Across Jurisdictions?

    Dec 1, 2022, 00:00

  • EE54 Haemophilia Lifetime Cost Comparison for Austria: Annual Drug Costs in Comparison With Projected Gene Therapy Costs

    Dec 1, 2022, 00:00

  • HTA233 Analysis: First Year of the New Early Access Authorization in France

    Dec 1, 2022, 00:00

  • HTA54 Incorporating Value of Health System Impact in Economic Evaluations of Therapies of Chronic Diseases

    Dec 1, 2022, 00:00

  • MSR84 Training Models for Machine-Enabled Systematic Literature Reviews: Do Large Datasets Always Give Better Results?

    Dec 1, 2022, 00:00

  • SA74 'How Easily Could You Obtain Proof of Diagnosis for Your Medical Condition?' Feedback From Individuals With Chronic Medical Conditions on a Digital Diagnosis Validation Feature

    Dec 1, 2022, 00:00

  • HTA122 Health-Related Quality of Life in the German Early Benefit Assessment

    Dec 1, 2022, 00:00

  • MSR15 Using Advanced Parametric Survival Models for HTA Submissions in the Face of Short-Term Patient Follow-Up

    Dec 1, 2022, 00:00

  • RWD138 Age-Distribution in ICD-10 Codes Used to Document Hospitalised RSV Burden in Infants in England

    Dec 1, 2022, 00:00

  • Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer

    Dec 1, 2022, 00:00

  • OP8 Developing Sustainable Partnerships Between Pharmaceutical Industry and Public and Non-Profit Organisations: Report of a Roundtable Discussion

    Dec 1, 2022, 00:00

  • EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands

    Dec 1, 2022, 00:00

  • HTA106 HTA and Reimbursement Timelines in the Republic of Ireland

    Dec 1, 2022, 00:00

  • EE93 Economic Consequences of the Implementation of HPV Screening in Bulgaria

    Dec 1, 2022, 00:00

  • MT1 FLT3 Inhibitors for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia: Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE191 A Budget Impact Analysis of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Atezolizumab-Bevacizumab as First-Line Therapy in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma in England

    Dec 1, 2022, 00:00

  • CO80 Surrogate Endpoints for Overall Survival in Cutaneous Squamous Cell Carcinoma: A Meta-Regression of Clinical Trials

    Dec 1, 2022, 00:00

  • SA3 Effect of Mortality on Cost-Effectiveness Modeling of Disease-Modifying Treatment for Alzheimer's Disease

    Dec 1, 2022, 00:00

  • EE6 Economic Burden of Severe Asthma in Adults and Children Treated With Omalizumab From 2012 to 2019

    Dec 1, 2022, 00:00

  • EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • PCR190 Health-Related Quality of Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis

    Dec 1, 2022, 00:00

  • EE641 Economic and Health-Related Quality of Life Consequences of Imaging and Surveillance Schedule in Seminoma Testis

    Dec 1, 2022, 00:00

  • EE675 Cost-Utility Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • HPR151 Has Project Orbis Facilitated Faster Access to Oncology Therapies in Great Britain Following 'Brexit'?

    Dec 1, 2022, 00:00

  • EPH41 Evaluating Population Health Priorities for Community Health Workers

    Dec 1, 2022, 00:00

  • P54 Antimicrobial Resistance Associated With Worse Outcomes in Hospitalized Adults With Pneumococcal Disease

    Dec 1, 2022, 00:00

  • HPR53 Changes to Early Access Scheme in Fran Early Learnings for Orphan Drugs

    Dec 1, 2022, 00:00

  • HTA209 Comparative Analysis of the Transparency Committee Opinions Concerning the Added Medical Benefit Levels Depending on the Therapeutic Areas: Distribution of Innovation and Trend Assessment for 2016-2021

    Dec 1, 2022, 00:00

  • RWD141 Exploration of Melanoma Patient-Generated Real-World Data Using an Ai-Based Social Listening Approach

    Dec 1, 2022, 00:00

  • CO143 Project Ideate: Creating a Novel Linked Real World Data Environment in Wales for Use in an Experimental, Retrospective Outcome-Based Agreement of a Breast Cancer Treatment

    Dec 1, 2022, 00:00

  • HTA32 Does a Major Added Benefit From the G-Ba Correspond to Positive Outcomes Across Major Markets? An Analysis Based on the Prismaccess Database

    Dec 1, 2022, 00:00

  • RWD162 Rationale of Level-Funded Health Plans for Women in US

    Dec 1, 2022, 00:00

  • HTA202 Learnings From First TC Opinions of Drugs Evaluated for EAP Under New Process

    Dec 1, 2022, 00:00

  • EPH8 Factors Associated With Oral Anticoagulant Switching in Patients With Atrial Fibrillation

    Dec 1, 2022, 00:00

  • CO115 Impact of Patient Blood Management (PBM) on the Reduction of Transfusion Requirements in Patients Undergoing Major Planned Orthopedic Surgery in Italy

    Dec 1, 2022, 00:00

  • HTA75 Cost-Minimization Analysis in Iron-Deficiency Anemia Comparing Intravenous Ferric Carboxymaltose to Standard of Care in Pregnant Women in Algeria

    Dec 1, 2022, 00:00

  • EE683 Evaluation of the Healthcare Resource Use of Haemodialysis Patients With and Without Pruritus in the UK

    Dec 1, 2022, 00:00

  • CO8 Ponatinib vs Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A Matching Adjusted Indirect Comparison

    Dec 1, 2022, 00:00

  • PCR286 Literature Review of Patient-Reported Outcome Measures in Multiple Myeloma: Trends and Considerations for Future Clinical Trials

    Dec 1, 2022, 00:00

  • HPR120 Negotiating New Therapeutic Indications in Italy: Which Impact on Drug Reimbursement Conditions and Timing?

    Dec 1, 2022, 00:00

  • MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in Oncology? Insights From a Cross-Tumor Case Study

    Dec 1, 2022, 00:00

  • EE633 A Targeted Literature Review of the Modelling Approaches and Challenges in Early-Stage Oncology Treatment Sequence Models

    Dec 1, 2022, 00:00

  • P10 Modelling Spillover Effects on Informal Carers: The 'Carer QALY Trap'

    Dec 1, 2022, 00:00

  • HTA119 Methodological Issues in Health Technology Assessment (HTA) for Re-Pricing in Japan

    Dec 1, 2022, 00:00

  • EE350 Selective Internal Radiation Therapy Using Y-90 Resin Microspheres vs Conventional Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: A Budget Impact Analysis in England

    Dec 1, 2022, 00:00

  • EE67 Cost Per Responder and Number Needed to Treat of iGlarlixi vs Premix BIAsp 30 in Algerian Setting

    Dec 1, 2022, 00:00

  • OP15 Assessment of the Clawback and Rebate Policies on the Efficiency of Greek Public Hospitals Between 2009-2019

    Dec 1, 2022, 00:00

  • EE282 Budget Impact Analysis of a Solution for Sealant in Spain

    Dec 1, 2022, 00:00

  • EPH183 Effect of Renin-Angiotensin System Inhibitors on Alzheimer’s Disease: A Population-Based Cohort Study

    Dec 1, 2022, 00:00

  • Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design

    Dec 1, 2022, 00:00

  • HPR121 By Any Genes Necessary: An Eventful 12 Months in the Gene Therapy Pipeline

    Dec 1, 2022, 00:00

  • SA39 RWE Generation: Have We Reached the Tipping Point to Drive Mainstream Adoption of Automated Electronic Health Record (EHR) Extraction Technology?

    Dec 1, 2022, 00:00

  • HPR18 Pharmacoeconomic Evaluation of Orphan Drugs in the United Kingdom, France, Italy, Turkey and Exploration of the Evaluation Process of Orphan Drugs in Algeria

    Dec 1, 2022, 00:00

  • HPR197 Designing a Performance-Based Risk Sharing Arrangement for Aducanumab

    Dec 1, 2022, 00:00

  • RWD120 Understanding Treatment Patterns, Disruptions and Potential Limitations of Tyrosine Kinase Inhibitors in ROS1+ Non-Small Cell Lung Cancer Patients in a Retrospective Review of United States Medical Transcription Records

    Dec 1, 2022, 00:00

  • HTA143 Are HTA Agencies Willing to Accept Single-Arm Trials as the Main Source of Clinical Evidence for the Assessment of Pediatric Orphan Drugs When Faced With Extenuating Ethical and Medical Circumstances?

    Dec 1, 2022, 00:00

  • SA61 Meta-Analysis of Sulodexide and Other Drugs in Prevention and Treatment of Post Thrombotic Syndrome

    Dec 1, 2022, 00:00

  • EE359 Real-World Utilization, Treatment Frequency, and Bleeding Outcomes on Damoctocog Alfa Pegol in Haemophilia A Care: Insights From a German Cohort Within the CHESS II Study

    Dec 1, 2022, 00:00

  • HTA132 Suitability of Value-Based Price Forecasting in a Crowded Landscape: A Case Study in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • MT16 Jumping Through Hoops: Critical Considerations on Current Draft Reimbursement Guidance for Medical Devices

    Dec 1, 2022, 00:00

  • EPH120 Clinical and Economic Burden of Severe Pneumococcal Disease Among Adults in Sweden: A Population-Based Register Study

    Dec 1, 2022, 00:00

  • EE29 Burden of Disease and Cost of Illness of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Bulgaria

    Dec 1, 2022, 00:00

  • EE216 Expenditure on Medicines for the Treatment of Multiple Myeloma in Catalonia for 2021

    Dec 1, 2022, 00:00

  • RWD123 Real-World Data About Treatment Pattern and Outcomes of Patients With Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in Fran Results From the Fregat Database

    Dec 1, 2022, 00:00

  • HPR109 Medicines Pricing in Bosnia and Herzegovina – What Could Be the Solution to Reduce Prices

    Dec 1, 2022, 00:00

  • HTA151 The NICE Cost Comparison Pathway - How Much Evidence Is Required to Meet the Criteria?

    Dec 1, 2022, 00:00

  • EE78 Mapping the Value for Money of Precision Medicine: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • CO85 Evidence Gap Analysis of the Burden of Illness and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

    Dec 1, 2022, 00:00

  • EE529 Modeling Studies of Human Papilloma Virus (HPV) Vaccines Cost-Effectiveness and Cervical Cancer Elimination– A Systematic Review

    Dec 1, 2022, 00:00

  • MT44 Extent of Use of Artificial Intelligence and Machine Learning Protocols in Cancer Diagnosis: A Scoping Review

    Dec 1, 2022, 00:00

  • EE106 Cost-Effectiveness Analysis of Bimekizumab in Patients With Moderate-to-Severe Plaque Psoriasis in Greece

    Dec 1, 2022, 00:00

  • HSD112 Can Risk Management Practices Foster the Role of Big Data and Data Analytics in Improving the Quality of Healthcare Services? Evidence From a Survey Among Healthcare Professionals

    Dec 1, 2022, 00:00

  • EE469 A Review of Cure Assumptions Implemented in Early-Stage Oncology NICE Appraisals

    Dec 1, 2022, 00:00

  • RWD157 Challenges and Opportunities of Using Electronic Health Records in Multi-Country Studies

    Dec 1, 2022, 00:00

  • CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis

    Dec 1, 2022, 00:00

  • MSR21 Exploration of the Impact of the Treatment Mechanism of Action on the Surrogate Relationship Between Progression Free Survival and Overall Survival in Metastatic Colorectal Cancer

    Dec 1, 2022, 00:00

  • EE403 Health and Economic Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in Germany: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • MSR14 Developing an Abbreviated WHOQOL-BREF for Patients With Major Chronic Diseases Using the IRT Model

    Dec 1, 2022, 00:00

  • EE277 Cost-Effectiveness of Lanreotide ATG Verse Octreotide for the Treatment of Acromegaly in China

    Dec 1, 2022, 00:00

  • EE170 Cost-Effectiveness of a Digital Diabetes Prevention Program (DDPP) in Prediabetic Patients

    Dec 1, 2022, 00:00

  • EPH162 Pilot Study to Assess the Prevalence of Advanced Gastrointestinal Stromal Tumor Identified Using German Claims Data

    Dec 1, 2022, 00:00

  • EE18 Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders

    Dec 1, 2022, 00:00

  • HPR115 When to Expect Economic Appraisal in France? A Study Based on 2021 Appraisal

    Dec 1, 2022, 00:00

  • HPR48 Reimbursement Policies Regarding Rare Diseases in Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • HPR193 Investigating the Correlation Between UK-Based Clinical Research and NICE Decision Making

    Dec 1, 2022, 00:00

  • HTA140 Current Changes in Europe Impacting Orphan Drugs Access: A Focus on the Latest Reforms in the EU4 and England

    Dec 1, 2022, 00:00

  • MSR118 Machine Learning Approaches Towards Identification of Phenotypes in Various Diseases Using Electronic Health Records

    Dec 1, 2022, 00:00

  • PCR185 The Role of Patients’ Advocacy Groups in the Italian Health Care Ecosystem: Present and Future Perspectives

    Dec 1, 2022, 00:00

  • EE364 Reduced Healthcare Resource Use in Patients With Chronic Insomnia After Treatment With a Digital Therapeutic With 2-Year Follow-Up

    Dec 1, 2022, 00:00

  • CO11 Comparison of Relapse Rates in Ulcerative Colitis Patients With Mayo Endoscopic Score of 0 or 1: Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR96 Effects of Intravenous Iron Infusion Frequency, Duration, and Safety on Quality of Life: Results of a Time Trade-Off Study in Patients With Iron Deficiency Anemia in China

    Dec 1, 2022, 00:00

  • EPH54 Prevalence and Association of Sociodemographic Determinants With the Risk of Developing Type 2 Diabetes in Saudi Arabia: A Web-Based Cross-Sectional Survey Study

    Dec 1, 2022, 00:00

  • EE599 Cost-Effectiveness Analysis of Trastuzumab Emtansine for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • EE200 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs (NNIADS): Trends in Decision-Analytical Models (DAM) for Modelling of Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2022, 00:00

  • RWD57 Epidemiological Study of the Burden of COVID-19 on Depression in Men (DIM) in Pre- and During COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • EPH157 Physical Activity Level in Association with Mental Health Before and During the Restrictions of the First Three Waves of COVID-19 Pandemic Among Hungarian Adults

    Dec 1, 2022, 00:00

  • EE503 Cost Implications of Hospice Care for Cancer Patients in Illinois Hospitals

    Dec 1, 2022, 00:00

  • EE280 Economic Burden of Hyperkalemia in Turkey

    Dec 1, 2022, 00:00

  • HTA208 Health Technology Assessment Impact on the Health Care System in Challenging Times in Ukraine

    Dec 1, 2022, 00:00

  • RWD130 The Effect of the COVID-19 Pandemic in the Prevalence of Diabetes Mellitus Type 1 and 2 in Children and Young Adults in Gree Real World Data from Greece

    Dec 1, 2022, 00:00

  • EPH92 Dysphagia Prevalence in Brazil, UK, China, and Indonesia and Dysphagic Patient Preferences

    Dec 1, 2022, 00:00

  • HPR84 The Impact of Medical Incidents on Follow-up Medical Treatment Under Different Medical Insurance Systems

    Dec 1, 2022, 00:00

  • EPH206 Strategies to Address Vaccine Hesitancy in Adults: A Systematic Review

    Dec 1, 2022, 00:00

  • EE521 Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Bone Conduction Implants (BCI): A Case Study of a Longitudinal Economic Analysis and a Markov Model-Based Simulation.

    Dec 1, 2022, 00:00

  • SA75 Exploring the Relationship Between Comorbidities and Alzheimer's Disease Progression Assessed Using the Clinical Dementia Rating Scale: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • CO131 Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in Finland (FINPAH) – A Descriptive Retrospective Real World Cohort Study Between 2008 and 2020

    Dec 1, 2022, 00:00

  • RWD116 Consequences of the Poor Anticoagulation Control of Patients With Non-Valvular Atrial Fibrillation Treated With Vitamin K Antagonists

    Dec 1, 2022, 00:00

  • EPH89 Epidemiology of Myxoid Round Cell Liposarcoma (MRCLS) in the European Union (EU27) – An Extrapolation From the United States (US) Surveillance, Epidemiology, and End Results (SEER) Research Database

    Dec 1, 2022, 00:00

  • Copyright/Subscription

    Dec 1, 2022, 00:00

  • EE372 Inside CKD – A Projection of Clinical and Economic Burden of Chronic Kidney Disease in Turkey

    Dec 1, 2022, 00:00

  • EE593 The Budget Impact of Introducing a Rapid Test for the Screening of Carbapenemase-Producing Organisms Among Hospitalized Patients in China

    Dec 1, 2022, 00:00

  • PCR233 The Case Studies of an Integrative Approach in Primary Healthcare of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID-19 Patients

    Dec 1, 2022, 00:00

  • SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • EE622 Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Prevention Interventions in Children: A Model Comparison Study

    Dec 1, 2022, 00:00

  • HTA27 Implications of an EU-Wide Joint Clinical Assessment on the Scope of the Decision Problem

    Dec 1, 2022, 00:00

  • EE189 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification

    Dec 1, 2022, 00:00

  • MT28 Effects of Mobile Health-Based Personalized Disease Management Program Intervened by Health Professionals Through a Mobile App and Telephone Interviews in Reducing Medical Costs

    Dec 1, 2022, 00:00

  • HPR214 Challenges of Measuring Healthcare System Resilience

    Dec 1, 2022, 00:00

  • EE483 Empagliflozin for Heart Failure Patients Irrespective of Ejection Fraction in Spain: A Cost-Effectiveness Study

    Dec 1, 2022, 00:00

  • EE94 Cost-Effectiveness Analysis of Vaccinating Against Herpes Zoster With Adjuvanted Recombinant Zoster Vaccine in Switzerland

    Dec 1, 2022, 00:00

  • PCR74 Development of Conceptual Frameworks and Patient-Reported Outcome Measures in Glycogen Storage Disease Type Ia (GSDIa)

    Dec 1, 2022, 00:00

  • CO103 Prognostic Models for Short-Term Annual Risk of Severe Acute Complications and Mortality in Patients Living With Type 2 Diabetes Using a National Medical Claim Database

    Dec 1, 2022, 00:00

  • Medtech

    Dec 1, 2022, 00:00

  • MSR26 The Use of Disease-Specific Health-Related Quality of Life (HRQOL)/ Patient Reported Outcomes (PROS) Scales in Rare Inflammatory Conditions (RICS)

    Dec 1, 2022, 00:00

  • EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France

    Dec 1, 2022, 00:00

  • HPR93 Turkiye-Based Health Economics and Outcome Studies Published in ISPOR

    Dec 1, 2022, 00:00

  • CO170 Efficacy and Safety of Golimumab in Pediatric Ulcerative Colitis: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE671 Budgetary Impact and Health Outcomes of Implementing New Treatment Guidelines for Heart Failure in Norway

    Dec 1, 2022, 00:00

  • EPH121 Future Trends of the COVID-19 Pandemics: What Should We Expect?

    Dec 1, 2022, 00:00

  • EPH175 Identification and Quantification of Atopic Dermatitis Patients With Insufficient Disease Control Under Conventional Systemic Treatments in Germany: A Feasibility Study

    Dec 1, 2022, 00:00

  • EE406 Colorectal Cancer Screening - Benefit-Harm and Cost-Effectiveness Analysis of Population-Wide Screening Strategies in Austria

    Dec 1, 2022, 00:00

  • EPH151 Clinical and Economic Benefits of Prompt Initiation of Single-Inhaler Triple Therapy in COPD Patients in England Following an Exacerbation

    Dec 1, 2022, 00:00

  • HPR198 Faster, Simpler, and Easier: Analyzing the Reform of the French Early Access Pathway

    Dec 1, 2022, 00:00

  • CO38 Transdiagnostic Analysis of Mental Disorder Symptoms Associated With Increased Frequency of Psychiatric Hospitalisation

    Dec 1, 2022, 00:00

  • SA25 Evolution of the Number of Metastatic Lung Cancer Patients before and during the COVID 19 Pandemic: A French National Hospital Database Analysis

    Dec 1, 2022, 00:00

  • HSD61 Trends in Discontinuation of Lipid-Lowering and Antihypertensive Therapies: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • EE116 Budget Impact Analysis of a Combination Analgesic for the Management of the Acute Mild to Moderate Pain in Italy

    Dec 1, 2022, 00:00

  • PCR288 Understanding Unmet Needs Relating to Unintentional Non-Adherence in Patients With Heart Disease – Review of Existing Evidence to Inform Patient-Centered Interventions

    Dec 1, 2022, 00:00

  • PCR155 A Theoretical Model on Pediatric Nurses’ Burnout, Wellbeing, and Patient Safety

    Dec 1, 2022, 00:00

  • HPR161 A Long-Term Forecast of the Economic Impact of Gene Therapies in France

    Dec 1, 2022, 00:00

  • EE302 Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma (uMPM) in the Netherlands

    Dec 1, 2022, 00:00

  • PCR13 Economic Advantages Associated With MS DMTs Mode of Administration

    Dec 1, 2022, 00:00

  • EE137 Evaluating the Effects of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model Risk Factor Progression Equations on Cost-Utility Outcomes in Type 2 Diabetes: Analyses Using the Prime Diabetes Model

    Dec 1, 2022, 00:00

  • PCR292 Health State Utility Values (HSUVs) and Health-Related Quality of Life (HRQoL) in People Living With HIV/AIDS (PLWH): A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • HSD74 Hospitalization Costs of Motor Neurone Diseases (MND) in Germany

    Dec 1, 2022, 00:00

  • SA14 Clinical Evidence on Corticosteroid Treatment Reported in the First Year of the COVID-19 Pandemic – Comparison of Clinical Trial Publications and Treatment Recommendation

    Dec 1, 2022, 00:00

  • PCR59 A Systematic Literature Review of Humanistic Burden in Huntington's Disease

    Dec 1, 2022, 00:00

  • HTA229 Use of Single-Arm Studies for Health Technology Assessment in Portugal

    Dec 1, 2022, 00:00

  • RWD106 Statistical Analysis Reproducibility Using Different Anonymization Techniques

    Dec 1, 2022, 00:00

  • CO27 Evaluation of Antiseptics and the Microbiological Environment Regarding Complications of Phlebitis Caused by Peripheral Cannulas

    Dec 1, 2022, 00:00

  • HPR70 Developing the Risk-Adjusted Capitation Payment for Patients With Diabetes Mellitus in China: Results From Administrative Data in Tianjin

    Dec 1, 2022, 00:00

  • CO40 Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Brolucizumab 6 Mg vs Aflibercept 2 Mg in the Kestrel and Kite Studies

    Dec 1, 2022, 00:00

  • RWD6 Follicular Lymphoma: Epidemiology and Real-World Practices in France (EPICART Study)

    Dec 1, 2022, 00:00

  • EPH22 A Systematic Literature Review of the Epidemiology Associated With Human Monkeypox in Children and Adults in India

    Dec 1, 2022, 00:00

  • PCR211 VOCAL (Views of Ovarian Cancer Patients and Their Caregivers-How Maintenance Therapy Affects Their Lives) Study: Cancer-Related Burden and Quality of Life of Caregivers

    Dec 1, 2022, 00:00

  • EE643 A Targeted Review of Cost-Effectiveness of Immunotherapies Used in Treatment of Metastatic Non-Small-Cell Lung Cancer Patients in EU-5, Sweden, and Switzerland

    Dec 1, 2022, 00:00

  • OP17 Analyzing Health System Resilience From the Perspective of Rare Diseases

    Dec 1, 2022, 00:00

  • PCR232 The Use of EuroQol EQ-5D in the Middle East and North Africa Region: A Systematic Review

    Dec 1, 2022, 00:00

  • HSD99 Analysis of the Balanced Scorecard's Customer Subdimensions in Health Care Organizations During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • PCR243 Facilitating and Accelerating Patient-Reported Outcomes (PRO) Selection to Use for Clinical Research and Rare Diseases (RD) - A European Rare Disease Research Coordination and Support Action (ERICA) Project

    Dec 1, 2022, 00:00

  • PCR160 Social Support as a Moderator of the Relationship Between Patient Activation, Self-Management of Diabetes, and Diagnosed Diabetes Complications, Among Adults With Type 2 Diabetes

    Dec 1, 2022, 00:00

  • HPR90 A Quasi-Experimental Study of the Effects of the Affordable Care Act (ACA) Marketplaces Subsidies on Access to Care and Healthcare Utilization of Nonelderly Adults With Chronic Conditions

    Dec 1, 2022, 00:00

  • PCR61 The Burden of Spinal Muscular Atrophy Type 2 (SMA2) on Caregivers in Japan, United Kingdom, and United States: Results of a Global Survey

    Dec 1, 2022, 00:00

  • EE25 Burden of Asthma According to GINA Treatment Steps in the French Constances Cohort

    Dec 1, 2022, 00:00

  • SA66 Patients' Perspective on Barriers Related to Delayed Diagnosis of Endometriosis: A Systematic Review of Qualitative Studies

    Dec 1, 2022, 00:00

  • EE174 Public Health Impact of Switching From a Trivalent to a Quadrivalent Inactivated Influenza Vaccine in Ecuador

    Dec 1, 2022, 00:00

  • EPH205 Characterizing the Burden of Disease in Patients With Asthma or COPD With Raised Versus Low Eosinophils: A UK Biobank Study

    Dec 1, 2022, 00:00

  • MT3 Comparison of Funding and Reimbursement Routes for Medical Devices in France, Germany, and Spain

    Dec 1, 2022, 00:00

  • P56 Impact of Comorbidities on the Over-Mortality of People Living With Human Immunodeficiency Viruses (PLHIV)

    Dec 1, 2022, 00:00

  • PCR54 Patient Preferences With Rheumatological or Dermatological Diseases Regarding Electronic Injection Devices for the Administration of Etanercept in Colombia

    Dec 1, 2022, 00:00

  • HSD76 Analysis of the Balanced Scorecard's External Subdimensions in Health Care Organizations During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HTA74 Novel Approach to Decision Making for Orphan Drugs

    Dec 1, 2022, 00:00

  • PCR262 Real-World Outcomes and Health Care Resource Utilization of Onasemnogene Abeparvovec for US Patients With Spinal Muscular Atrophy Type 2: Results of a Retrospective Chart Review Study

    Dec 1, 2022, 00:00

  • EE265 Health, Productivity and Budget Impact of Vaccinating 50-64 Year Old Employees in Austria Against Herpes Zoster With Recombinant Zoster Vaccine

    Dec 1, 2022, 00:00

  • EE618 Healthcare Resource Utilisation and Economic Burden Associated With Lupus Nephritis in China: A National Claims Database Study

    Dec 1, 2022, 00:00

  • EE36 Impact of Home Hospitalization on the Cost of Care for 1ST Line Treatment of Locally Advanced or Metastatic HER2+ Breast Cancer

    Dec 1, 2022, 00:00

  • EE327 Cost-Effectiveness Analysis of Cemiplimab for Patients With Advanced Non-Small Cell Lung Carcinoma in Spain

    Dec 1, 2022, 00:00

  • Public Health

    Dec 1, 2022, 00:00

  • PCR156 Attitude Towards Blood Donation Among the Hungarian Population

    Dec 1, 2022, 00:00

  • EE542 Health Experiences, Well-Being and Preferences in Health Priority Settings

    Dec 1, 2022, 00:00

  • HPR59 The Pharmaceutical Reimbursement and Access Pathways in the 27 EU Member States: Who Is Ready for Joint EU HTA?

    Dec 1, 2022, 00:00

  • CO110 Systematic Literature Review (SLR) and Meta-Analysis (MA) of Clinical Outcomes for Second-Line and Higher (≥2L) Targeted Therapies for Advanced Colorectal Cancer (aCRC)

    Dec 1, 2022, 00:00

  • EE478 Do Triple Single-Pill Combinations Make a Difference in Treatment Adherence, Outcomes and Healthcare Resource Utilization in Hypertension? A Real-World Analysis of Patients on Perindopril/Amlodipine/Indapamide in Italy

    Dec 1, 2022, 00:00

  • SA71 Validation Study of Algorithms to Identify Cancer Metastasis/Recurrence in Patients With High-Risk HR+/HER2- Early Breast Cancer (EBC) Using Japan Nationwide Hospital-Based Databases Owned By National Hospital Organization

    Dec 1, 2022, 00:00

  • HPR158 Progression Free Survival and Duration of Treatment as a Proxy of Disease Severity: Use of These Variables to Determine Price Benchmarks

    Dec 1, 2022, 00:00

  • RWD59 Disparity in Breast Cancer Female Undergoing Reconstructive Procedures: A Real-World Analysis

    Dec 1, 2022, 00:00

  • RWD103 Real-World Results of Reimbursed Immune Checkpoint Inhibitors in Taiwan’s Health Insurance System

    Dec 1, 2022, 00:00

  • RWD52 Relevant Real-World Evidence Landscaping and Data Source Assessment for Vitiligo Patient Research in Europe

    Dec 1, 2022, 00:00

  • Incorporating Informal Care Considerations in HTA

    Dec 1, 2022, 00:00

  • MSR55 Extraction of Ejection Fraction From Clinical Notes Using a Pretrained Albert-for-Question-Answering Model

    Dec 1, 2022, 00:00

  • EE139 Cost-Effectiveness of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Cancer Treatment: A Systematic Review

    Dec 1, 2022, 00:00

  • P43 Navigating the Maze of Standard and Novel Population-Adjusted Indirect Comparison (PAIC) Methods

    Dec 1, 2022, 00:00

  • CO15 A Matching-Adjusted Indirect Comparison of Efgartigimod Versus Ravulizumab for Generalized Myasthenia Gravis

    Dec 1, 2022, 00:00

  • EE5 Cost-Utility Analysis of Aripiprazole, Olanzapine Branded Generic, and Olanzapine Generic on Stable Phase of Schizophrenia Patient at Mental Health Hospital in Jakarta

    Dec 1, 2022, 00:00

  • EE337 An Economic Assessment of Incorporating an Acellular Hexavalent Vaccine as Part of the National Immunization Program of Peru

    Dec 1, 2022, 00:00

  • SA73 Addressing Unmet Needs of Patients With Neuronopathic Gaucher Disease Type 2 and Type 3: Creation of the GARDIAN Patient Registry

    Dec 1, 2022, 00:00

  • CO114 Health Outcomes and Costs Related to the In-Hospital Procedures for the Management of Tricuspid Valve Disease in Spain

    Dec 1, 2022, 00:00

  • HSD17 Treatment Pattern of the Opioid Injection Prescriptions in South Korea

    Dec 1, 2022, 00:00

  • HTA222 How to Increase the Public Legitimacy of Healthcare Resource Allocation Processes: Lessons From an Israeli Case Study

    Dec 1, 2022, 00:00

  • Real-World Evidence to Inform Healthcare Decision Making

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33 (current)
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »